<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Symptomatic patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and 10-30% blasts in the bone marrow were treated with low-dose AraC (2 x 10 mg/m2 subcutaneously (sc) days 1-14) and GM-CSF (fully glycosylated, Sandoz/Schering-Plough, 2 x 150 micrograms protein/day sc) given either subsequently (days 15-21) or simultaneously (days 8-14 and one week rest) </plain></SENT>
<SENT sid="1" pm="."><plain>Evaluations were carried out after three courses (nine weeks); responding patients could be continued for two further cycles </plain></SENT>
<SENT sid="2" pm="."><plain>Eighty-two patients with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> and excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), with (RAEBt) or without transformation, were evaluable: 45 RAEB and 37 RAEBt, mean age 64 years (range 17-80 years) </plain></SENT>
<SENT sid="3" pm="."><plain>A complete remission was achieved in 14 cases (17%), 11 had a good response (13%), and 12 a partial response (15%) </plain></SENT>
<SENT sid="4" pm="."><plain>Stable disease was found in 21 cases (26%) </plain></SENT>
<SENT sid="5" pm="."><plain>There were 12 cases of toxic <z:hpo ids='HP_0011420'>death</z:hpo> (15%), progression was noted in eight patients (10%), and <z:hpo ids='HP_0011420'>death</z:hpo> due to disease in three (4%) </plain></SENT>
<SENT sid="6" pm="."><plain>No difference existed between the two treatment arms with respect to response </plain></SENT>
<SENT sid="7" pm="."><plain>Major adverse events during treatment were haemorrhage (25%), <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (23%), and <z:hpo ids='HP_0001945'>fever</z:hpo> with GM-CSF (21%) </plain></SENT>
<SENT sid="8" pm="."><plain>GM-CSF did not induce <z:mpath ids='MPATH_336'>leukaemia</z:mpath> nor contribute to haemorrhage induced by AraC, but gave rise to an overall response rate of 46% which is high and relatively durable as compared to other treatments in this disease </plain></SENT>
</text></document>